Block 1 Flashcards
(126 cards)
Chronic granulomatous disease
• Mutation in NADPH oxidase complex
• Children typically detected because repeated bacterial infections in infancy
• When testing oxygen to superoxidase production using NBP test their white cells do not convert oxygen to superoxide
o Cells look white when challenged, normal cells will look blue
• Phagocytes fail to produce adequate levels of oxygen radicals and hydrogen peroxide upon phagocytosis of microbes
Glucose 6-P dehydrogenase deficiency
- This enzyme is involved in the HMP shunt
- If mutation in this enzyme it blocks the conversion of oxygen to superoxide and gives child who is phenotypically like chronic granulomatous child
- Can cause increase susceptibility to infection
MPO deficiency
- Deficiency in myeloperoxidase
- Not as severe because other antimicrobial agents can be produced
- Still causes increased susceptibility to infection
Glutathione reductase, glutathione peroxidase deficiencies
- Need coupling of pathways for this to work
* Without coupling the conversion of oxygen to superoxide comes to a halt
Chediak-higashi syndrome
- Abnormal fusion of phagosomes with lysosomes
- Failure to kill ingested microbes
- Impaired MPO
- Impaired myeloperoxidase
- Faulty lysozomal fusion
Leukocyte adhesion deficiency (LAD)
- Group of disorders where interaction of leukocytes with vascular endothelium is disrupted
- Due to autosomal recessive mutation that results in faulty expression of CD18 (CD11a/CD18 and CD11b/CD18) are present on neutrophils and monocytes and are pivotal to attachment to endothelium for diapedesis into the tissues
- Loss of adhesive interactions greatly inhibits the ability of T cells to effectively mount immune responses, as manifested in the clinical disease lymphocyte adhesion deficiency (LAD).
IRAK4 deficiency
- Increase sensitivity to certain infections
- Increased sensitivity to respiratory viruses and other agents
- Important to recognize that there are a number of inheritable mutations that lead to deficient innate immune responses.
Mechanisms of immune evasion
o Pneumococcus
o Capsular polysaccharide inhibits phagocytosis
• Resistance to reactive oxygen intermediates in phagocytes
o Staphylococci
o Production of catalase which breaks down reactive oxygen intermediates
• Resistance to complement activation (alternative pathway)
o Neisseria meningitides
Sialic acid expression inhibits C3 and C5 convertases
o Steptococcus
M protein blocks C3 binding to organism and C3b binding to complement receptors
• Resistance to antimicrobial peptide antibiotics
o Pseudomonas
o Synthesis of modified LPS that resists action of peptide antibiotics
• Prevent cell sloughing
o Neisseria gonorrheoeae
o Increase adhesion molecules on vaginal epithelial cells – decreases sloughing
Pathogen sabotage of complement
• Pathogens have learned to use and abuse complement components
• Evasion from destruction by complement
• Evolved ways of attracting factor H to the surface
o Example – candida yeast
o Factor H will stop complement in its tracks – complement cannot be activated
• Helicobacter incorporates the MAC
o Lytic important for destruction of helicobacter
o CD59 is incorporated
• Some bacteria have found ways to attach sialic acid to their surface (taken from dying cells or making sialic acid), once there is sialic acid on the bug properitin does not like to bind
Not a good surface for the fixing the complement cascade
Hemolytic Uremic Syndrome
• Thrombocytopenic, microangiopathic (TMA) hemolytic anemia with kidney injury
• Thrombocytopenic = low platelets
• Hemolytic anemia = Red blood cells lysing (breaking open)
• Microangiopathic = caused by narrowing or obstruction in small blood vessels
• Uremic = retention in the blood of waste products normally removed by the kidneys
• Atypical or recurrent Hemolytic Uremic Syndrome is caused by complement system “deregulation”
o Low levels of or dysfunctional complement cascade inhibitors
o Factor I, Factor H and MCP are important in the atypical hemolytic uremia syndrome
o Specifically the alternative pathway
• *‘typical’ HUS, or diarrhea associated HUS, caused by a Shiga toxin produced by E.coli bacteria, is a purely pediatric illness
o Diarrheal HUS is a one-time thing, kids recover
o If no bacteria or shiga toxin is identified in a child’s stool then diagnosis of aHUS is made
• HUS is permanent genetic mutation causes low levels of or dysfunctional factors H, factor I, or membrane co-factor (MCP)
• Some environmental ‘trigger’ event causes initial injury to lining of blood vessels (endothelium), activating complement cascade
o Once the cascade has been activated it can not be shut off
o Triggers include infections, pregnancy, medications, surgical procedures, and birth control pills.[4] importantly, gastroenteritis is a potential trigger of aHUS
• Uncontrolled complement activation, MAC incorporation and damage to cells lining blood vessels
• Cell injury attracts white blood cells and exposes thrombogenic parts of cells
• Platelet accumulation and activation of coagulation cascade (formation of clots)
o Thrombocytopenia
Multiple intracapillary glomerular thrombi
o Platelets are main component of clot, creating lots of clots low levels of platelets
• Clots and narrowing of blood vessel cause injury to blood cells passing through (lysis)
o Hemolytic Anemia
• Poor filtration across glomerular membrane
o Uremia or Renal failure
Decreased or absent urine production
Become uremic and have retention of waste products, potassium, urea, creatinine
Elevated creatinine – can not filter across the membrane
• Genetics
o Abnormal genes causes a problem with the factors
o Unclear if monogenic or polygenic
o Most commonly autosomal dominant
o Mutations in genes for FH and FI (produced by liver), and MCP (glomerular expression)
FH mutations most common
aHUS onlt develops in ~ 50% of patients with a factor H mutation
Nearly 70% with aHUS have a mutation in one of the currently defined genes
• Prognosis
o Recurrent and persistent
o Renal failure
• Treatment
o Supportive Care
Blood transfusions
Fluid, electrolyte, and blood pressure management
Dialysis
o Correct abnormality in complement pathway
Plasma therapy
Complement cascade inhibitor- Eculizimab
• Medication used more commonly for aHUS
Organ transplant
C3 deficiency
• Consequence: loss of opsonization and MAC (its all gone –complement does not function)
• Clinical manifestations: pyogenic infections, especially Staph, Neisseria
o Problems with all extracellular bacteria
• C3 deficiency is the most debilitating, not surprising considering its central and indispensable role in the cascade, potentially leading to severe bacterial infections
C1 inhibitor (C1NH) deficiency
• Consequence: lose C1 and kallikrein regulation; kininogen cleaved to release bradykinin
o C1NH is the molecule that dissociates C1q from C1R and C1S
o Also an inhibitor of the coagulation cascade
o Without this inhibitor will have a lot of bradykinin released – molecule that induces vasoconstriction
Cannot use Benadryl or epinephrine because different pathway
Can only be cured by fresh plasma or adding C1 inhibitor
• Clinical manifestations: hereditary angioedema (HAE or HANE)
• C1-INH (or C1 esterase inhibitor) deficiency leads to ‘hereditary angioneurotic edema,’ or HANE (more commonly HAE).
o C1-INH is also an inhibitor of bradykinin production, which in combination with a proteolytic fragment of C2 (C2 kinin or C2b) can lead to intermittent acute edema in skin and mucosal tissues, potentially leading to airway obstruction.
CD59 deficiency
• Consequence: no inhibition of MAC
o Inhibitor of MAC, found on the surface of the cells
• Clinical manifestations: hemolysis, thrombosis (PNH: paroxysmal nocturnal hemoglobinuria)
o Without inhibition of MAC, can have PNH – this is life threating
• Deficiency in one of the MAC components leads to heightened susceptibility to Neisseria infections
• A deficiency in DAF or CD59 (direct, via absence of the gene or indirect, via the absence of the enzyme that forms GPI (glycophosphatidylinositol) tails) causes paroxysmal nocturnal hemoglobinuria (PNH)
o Characterized by intravascular hemolysis and presumably caused by unregulated MAC formation.
o Patients have dark urine, which is most pronounced in the morning (due to pH changes in the blood at night resulting in increased MAC production as well as overnight urine concentration.)
C1qrs, C4, C2 deficiency
• Consequence: lose classical pathway
o Alternative pathway can take over, for immune defense it is not that big of problem
• Clinical manifestations: SLE (lupus)
o Without removing the immune complex you can end up with immune complex disease
o Also has a strong association with lupus
o If C1q is missing it is an association with lupus – apoptotic cells are not being removed as efficiently as they are when C1q is around
o Tissue damage and failure to remove the bleb – association with autoimmune disease
• C2 and C4 deficiencies do not generally result in heightened susceptibility to infections, but there is an increased risk of immune-complex diseases (like SLE), perhaps initiated by a delay in uptake and removal of antibody-antigen complexes
• Note that C2 deficiency is the most common complement disorder.
Factor H, I deficiency
• Consequence: C3 deficiency, factor H mutations important in many clinical situations
o Factor H is important inhibitor of C3 convertase
o When you have deficiency of Factor H and Factor I you will have a C3 deficiency
o Complement will get used up because you will have amplification
o Factor H and I are competing with Factor B to limit the amount of activation of the complement cascade
• Clinical manifestations: infections, inflammation, macular degeneration, AHUS
o Leads to same thing as C3 deficiency
• Factor I or Factor H deficiency actually leads to a C3 serum depletion by the reduced capacity of the system to inhibit C3b,Bb convertases once they spontaneously form by the ‘tickover’ mechanism
o Because Factor H is involved in dampening responses, continual activation of the alternative pathway in Factor H-deficient (or even certain alleles) folks is associated with aging macular degeneration (AMD).
• Mutations found in Factor H are associated with macular degeneration
PIG-A deficiency
• Loss of GPI anchor results in disease
• PIG-A - enzyme that puts the lipid tail onto the backend of certain molecules
o Molecules on the surface with phosphatidylinositol N-acetyl glucosaminyl transferase subunit A tails
o This enzyme that puts the lipid tails on can be defective
• All of the GPI linked molecules will not be on the surface
o Two important GPI linked molecules are CD59 and DAF
• This leads to PNH (paroxysmal nocturnal hemoglobinuria hemoglobinuria)
o This is worse PNH than if there is simply a defect in the gene that encodes CD59
o Just missing CD59 will have PNH, worse if missing both CD59 and DAF
• Deficiency in an enzyme (PIG-A) results in failure of expression of ALL gpi-linked proteins (e.g. CD59 and DAF)
• When these two are missing PNH is exacerbated (CD59 deficiency itself leads to PNH, but the disease is exacerbated when DAF is missing as well).
• PIG-A problems may come from total deficiency or somatic mutations
PNH
- If just missing CD59, MAC does not form very often on its own but it cam
- Especially at night when pH of blood changes, encourages molecule of MAC to form
- Can insert in RBC and end up with hemolysis
- Without DAF in addition to deficiency in CD59 there will be a defect in the blocking of the amplification loop that is forming on cells
- Cd59 is on surface on RBC, without it will have some deposition of C3b on the surface of the RBC
- Treated with Eculizamab because it will block the splitting of C5 into C5b and C5a
- Given their deficiency in surface CD55, PNH erythrocytes are susceptible to complement activation through C3 tick over and the alternative pathway, as well as through any other complement pathway
- After initial C3 activation and subsequent C3b binding to erythrocyte surface, the complement cascade may proceed toward the MAC formation, which is not inhibited due to the lack of CD59
- As a result PNH erythrocytes succumb because of MAC-mediated intravascular hemolysis
Hereditary angio(neurotic) edema
• Inhibitor is part of the bradykinin cascade and complement cascade
• Activation of kallikrein → cleavage of kininogen to generate bradykinin, vasoactive peptide
• Activation of proactivator → cleavage of plasminogen to generate plasmin → cleavage of C2b to generate C2 kinin, vasoactive peptide
• Cleavage of plasminogen to generate plasmin → activation of C1 → cleavage of C2 to generate C2b → cleavage of C2b to generate C2 kinin, vasoactive peptide
• Treatment of HAE
o Fresh plasma
o Purifies C1 inhibitor from plasma
Kidney transplants
Antibodies play the major role in hyperacute and chronic organ rejection (typical rejection is T cell-mediated)
o The typical acute rejection of a kidney graft is usually due to cytotoxic T cell
Acute and chronic rejection of graft can be due to antibodies
• Blocking C’ activation can ameliorate rejection episodes
• Complementary determining regions – heavy and light chain V will be different for each antibody
• Even our monoclonal antibodies will be different because of the diverse region
• Eculizumab being used in HUS, PNH and also being used in renal transplantation
If you detect antibodies against the donor kidney – MHC antigens – can use Eculizumab and block the destruction of the kidney by blocking the formation of MAC
Encapsulated bacteria
• E.g. Neisseria
• MAC is important for the defense against Neisseria
• When we use Eculizumab we can often end up with infections of Neisseria
• Neisseria have anti-opsonic functions of their capsules
• Whenever we use Eculizumab it is good to vaccinate against Neisseria so that the patient has antibodies
o Lost C5a and lost MAC
o Only have opsinization and whatever inflammation from C3a
o Need to rely on vaccinating so we ensure we have antibodies
• C’ is important for defense (MAC especially) so we must vaccinate C’ suppressed people
• Encapsulated bacteria resist uptake by neutrophils and avoid engulfment
• Encapuslated bacteria like Neisseria resist phagocytosis, so MAC is quite important for defense against these nasty bugs.
• Vaccination will generate antibodies that fix C’ and C3b, hopefully overcoming the phagocytosis resistance by opsonization
Penicillin hypersentitivity
- Penicillin is a small, beta-lactam ring antibiotic with potent bactericide activities.
- It blocks the last step of cell wall biosynthesis in Gram-positive bacteria and has proven instrumental in the success of chemotherapeutical management of infectious diseases.
- Penicillin is a hapten that normally cannot induce an immune response.
- It is also a drug, however, that binds to plasma proteins (“carrier”) at a certain concentraiton shortly after administration.
- While most people are naturally tolerant to their plasma proteins, in some the drug coupled to its carrier induces immune recognition and, typically, IgE production (sensitization).
- Upon re-exposure to the drug, circulating IgE can bind to the free, soluble penicillin (hapten recognition), the complex is bound by Fce receptors on mast cells which induces rapid degranulation and release of histamine and other inflammatory mediators that cause an immediate hypersensitivity reaction, occasionally leading to fatal anaphylactic shock. 3-6% of people react to penicillin at least in a skin test, and about 0.004-0.015% develop anaphylactic shock.
Omenn syndrome
• SCID caused by Rag-1 or Rag-2 mutations
o If the recombinase (RAG1 or RAG2 gene mutations) is defective then will not have recombination and will not create immunoglobulins and T cell receptors
o When you do not have recombination, you will not be able to progress in development of lymphocytes
Not only lymphocytes with TCR, no lymphocytes at all
• SCID – Severe Combined Immune-Deficiency (because you do not have T cells or B cells)
• Symptoms:
o Erythroderma, desquamation, alopecia, chronic diarrhea, failure to thrive, lymphadenopathy, hepatosplenomegaly
• Laboratory:
o No B-cells, oligclonal T-cells, hyper IgE, eosinophilia
• Cause:
o Hypomorphic RAG gene mutations
• Treatment:
o Bone marrow transplantation, gene therapy (exp)
• RAG-1 mutations affect DNA binding or catalytic activity
• RAG-2 mutations affect chromatin accessibility
o RAG 2 has unique domain, if this is mutated that results in catalytically active complex that cannot be targeted appropriately
• Some mutations will be hypermorphic – result in significant loss of activity
• Some lower levels rearrangement can happen can generate a few T cells – these will expand and will give rise to relatively normal looking lymphocyte number but severely reduced diversity of clonality (autoclonality)
o Losing diversity – lose ability to fight diverse antigens and lost many regulatory features and networks in lymphocyte activity
o Hyper-activity of immune system – hyper reactive scenarios
o Due to reduction in diversity and disturbing lymphocyte regulatory pathways
Combined scid + radiation sensitivity
• Caused by Artemis/DNA ligase 4 mutations
o Not able to join the ends because of defects in NHEJ
o RAG activity is intact, defect in artermis or ligase 4
• Symptoms:
o Neonatal scid
Childhood EBV-lymphoma
o Adult-onset immunodeficiency
o Microcephaly (Ligase 4)
o Radiation sensitivity
o Genomic instability
• Laboratory:
o No T/B-cells
o No, or little, circulating Ig
• Cause:
o Complete or hypomorphic Artemis or hypomorphic DNA ligase 4 gene mutations
• Treatment:
o Bone marrow transplantation, gene therapy (exp)
• These patients are radiation sensitive due to inability to fix DNA end breaks
o Cannot repair DNA breaks, NHEJ is universal pathway important in gene rearrangement and in general DNA break repair
Type 2 hyper IgM syndrome
• Deficiency associated with AICDA mutations
o Process occurring in activated B cell
o Can generate primary responses, cannot switch to other isotypes and cannot switch to higher level antibodies
• Autosomal
• Symptoms:
o Repeated bacterial pneumonia, otitis, lymphadenopathy
• Laboratory:
o Normal B/T-cells,
o Hyper IgM,
o No other Ig isotypes
• Cause:
o Inactivating AID gene mutations
• Treatment:
o I.v. immunoglobulin
• Will generate the germinal centers because the activation of the process is normal
• Inside the germinal centers the process is defective because of the mutation of enzyme